Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Elite Pharma Inc (ELTP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 139,613
  • Shares Outstanding, K 917,900
  • Annual Sales, $ 12,500 K
  • Annual Income, $ -680 K
  • 36-Month Beta -0.05
  • Price/Sales 15.83
  • Price/Cash Flow N/A
  • Price/Book 5.32
  • Price/Earnings ttm 3.83
  • Earnings Per Share ttm 0.04
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 02/09/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1390 +9.42%
on 04/06/17
0.1549 -1.81%
on 03/30/17
+0.0068 (+4.68%)
since 03/27/17
3-Month
0.1250 +21.68%
on 03/03/17
0.1580 -3.73%
on 03/20/17
-0.0029 (-1.87%)
since 01/27/17
52-Week
0.1100 +38.27%
on 07/27/16
0.3950 -61.49%
on 07/13/16
-0.1729 (-53.20%)
since 04/27/16

Most Recent Stories

More News
Elite Pharmaceuticals Files ANDA for Pain Product

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that it had filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for a generic...

ELTP : 0.1521 (-0.59%)
Elite Pharmaceuticals, Inc. Reports Results for Third Quarter of Fiscal Year 2017

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), announced results for the quarter ended December 31, 2016, the third quarter of its 2017 fiscal year.

ELTP : 0.1521 (-0.59%)
Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study for a Generic OxyContin(R)

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today reported positive topline results from a pivotal bioequivalence fed study initiated in November 2016. The topline results indicate...

ELTP : 0.1521 (-0.59%)
Elite Provides Update on SequestOx(TM) New Drug Application

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the Company met with the U.S. Food and Drug Administration (the "FDA") on December 21, 2016 for an end-of-review meeting...

ELTP : 0.1521 (-0.59%)
Elite Pharmaceuticals Files ANDA for Hydrocodone and Acetaminophen Combo

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for a generic...

ELTP : 0.1521 (-0.59%)
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2017 and Provides Conference Call Information

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the six months...

ELTP : 0.1521 (-0.59%)
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 2nd Quarter 2017 Financial Results on November 10, 2016

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that...

ELTP : 0.1521 (-0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Support & Resistance

2nd Resistance Point 0.1579
1st Resistance Point 0.1550
Last Price 0.1521
1st Support Level 0.1471
2nd Support Level 0.1421

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.